Purpose: Pathologic fractures occur in 5-10% of pediatric osteosarcoma (OS) cases and have historically been considered a contraindication to limb salvage. Our purpose was to describe the radiographic features of pathologic fracture and examine its impact on local recurrence rates, functional outcomes, and overall survival.
INTRODUCTION
Osteosarcoma (OS) is the most common bone cancer in children and adolescents with about 400 new cases annually in the United States. 1 Pathologic fractures occur in 5-10% of cases at the time of diagnosis or during neoadjuvant chemotherapy. 2 Traditionally, pathologic fracture Abbreviations: HDMTX, high-dose methotrexate; MSTS, Musculoskeletal Tumor Society; OS, osteosarcoma was a contraindication for limb salvage surgery and was thought to be associated with local recurrence. 3 Recent studies have shown that pathologic fractures are not a contraindication to limb salvage surgery with local recurrence rates in these patients ranging between 10% and 25%. 2, [4] [5] [6] [7] [8] To date, little information is available concerning the types of fractures patients sustain and the functional outcomes of patients with fractures. We investigated the types of pathologic fractures, treatment modulation, local recurrence rates, functional outcomes, and overall survival. 
TA B L E 1
Patient, tumor, and management characteristics of the pathologic fracture group and nonpathologic fracture
MATERIALS AND METHODS
Following the IRB approval, we retrospectively reviewed medical records and diagnostic imaging of OS patients who were treated patients. Twenty-four patients showed a poor response to chemotherapy and 23 showed a good response. Table 2 summarizes the characteristics of pathologic fractures.
Characteristics of pathologic fractures
Twenty-eight fractures (76%) occurred at diagnosis; 9 fractures (24%) occurred during neoadjuvant chemotherapy. The most common sites for fracture were the distal femur (n = 14) and proximal humerus (n = 14). Most fractures occurred through the tumor (n = 34), but three fractures occurred near the tumor periphery.
TA B L E 2 Characteristics of pathologic fractures

Fracture time
Diagnosis 28
During therapy 9
Fracture location
Distal femur 14
Proximal humerus 14
Mid-femur 3
Proximal tibia 2
Femoral neck 1
Proximal femur 1
Radius and ulna 1
Distal tibia 1
Fracture location relative to primary tumor Only 13 fractures showed angulation, most commonly medial angulation (n = 6). Most fractures showed minimal to partial healing (n = 21). Twelve fractures showed no signs of healing while only four showed full healing. Fracture types were highly variable with oblique (n = 8) and transverse (n = 5) being the most common.
Management of their fractures was highly variable. Most patients received either a cast (n = 9), sling (n = 8), or a brace (n = 7).
Other managements included internal fixation (n = 3), bed rest (n = 3), traction (n = 1), surgery (n = 1), suspension (n = 1), boot (n = 1), splint (n = 1), and an immobilizer (n = 1). One patient had a healed fracture. patients were deceased and 14 (39%) were alive.
Management and outcomes in patients with and without pathologic fractures
In the non-fracture group, 40 patients underwent limb salvage surgery and 8 had an amputation; 2 patients did not undergo surgery due to extensive metastatic disease. Of the 48 patients who had surgery, 7 (14.6%) experienced a local recurrence. Thirty-four patients (68%) developed distant recurrent disease. Overall, 27 (54%) patients were deceased, and 23 (46%) patients were alive. Table 3 shows the association between prognostic factors and frac- Fig. 1) and number of distant recurrences were not statistically significant between the two groups (P = 0.96 and 0.410, respectively). The fracture group had a lower cumulative incidence rate of local recurrence (2.9%) than the nonfracture group (14.6%) even though it was not significant (P = 0.131) (Fig. 1) . Thus, the two groups had similar prognosis, and pathologic fracture was not an indicator of poor patient prognosis.
Statistical results
DISCUSSION
Pathologic fractures occur in OS patients either spontaneously or as a result of minimal trauma. 15 In our study, the majority of patients (76%) presented at diagnosis of their primary disease with a pathologic fracture. This is consistent with findings in other studies. 2, 5, 16 To date, less data have been reported on the types of fractures sustained by these patients. We found that type of fracture was highly variable as was fracture healing; 62% of our patients showed evidence of fracture healing. In contrast, Ferguson et al. reported 30% of fracture healing in their patients. 5 It has been suggested that chemotherapy may assist in the healing of these fractures prior to surgery. 15 Fracture healing has also been associated with more favorable prognosis, including increased overall survival and decreased local recurrence. 17 In our study, of the patients who showed no signs of healing (n = 12), 50% were alive at the last follow-up. Of the patients who had full fracture healing (n = 4), 50% were alive at the last follow-up.
The management of pathologic fractures in children with OS has been addressed by several authors. Jackson et al. proposed that any type of management should be done after a biopsy and histological diagnosis are obtained. 18 Saraph and Linhart proposed that the management of pathologic fractures should take into consideration the pain and comfort of the child, local control of the lesion, stabilization and anatomical alignment of the fracture, fracture union, and functional restoration. 19 Ruggieri et al. proposed that fractures should be initially managed by cast or external fixation to avoid microscopic spread of the tumor. 17 The management of pathologic fractures in our study was highly variable. The majority of patients underwent closed management of their fracture, mainly using braces, slings, or casts.
Because our result regarding fracture management was so variable, we propose that for our institution in the future, we should institute a protocol to investigate fracture management further.
Two prominent studies stated that pathologic fracture was significantly associated with an increased local recurrence rate. 2, 16 However, multiple recent studies have contradicted their results. 3, 4, [6] [7] [8] [20] [21] [22] 24, 26 Our results support these more recent studies. We found that the local recurrence rate among pathologic fracture patients was lower than those without fracture. This could be due to surgeons resecting wider margins in pathologic fracture patients than those without fracture.
While more patients with pathologic fracture underwent amputation, according to detailed preoperative records, the fracture was not an indication for amputation. Reasons for amputation included localized and metastatic tumor burden, tumor progression, or involvement of neurovascular structures. Statistical analysis showed a significant difference in the number of patients with amputations in the pathologic fracture group compared to the nonfracture group. We attribute this difference not to the pathologic fracture, but due to potentially more aggressive disease in these patients. A statistically significant greater proportion of patients with pathologic fracture (73%) showed a poor response to chemotherapy compared to nonfracture patients (51%). Patients with pathologic fracture in our study appear to have more aggressive local disease, predisposing them to fracture, and demonstrate poor response to chemotherapy, which was an indication for amputation. Even though there was a significant difference found between responses to chemotherapy, we found no difference in overall survival between the two groups. In a recent study, Bishop et al. report that perhaps a histological response to neoadjuvant chemotherapy may not be an accurate long-term prognostic marker for patients with OS. 27 This could be an explanation for why the fracture group, despite having a poorer histological response, did not have worse overall survival.
Chemotherapy regimens varied greatly in and between both groups. This could affect overall survival and outcomes. However, the majority of patients in both groups were grouped into the OS91, OS99, or OS2008 clinical trials. Results from the OS99 trial showed no significant difference in outcomes from the OS91 trial. 10 Results from the OS2008 trial have still not been published, so at this time we are not certain whether the OS2008 trial showed superior outcomes to the previous trials. Traditional systemic chemotherapy regimens for OS have not changed greatly in the last three decades. 28 Overall survival has improved from the 1970s to the present, but Hagleitner et al. attribute this to improved supportive care for chemotherapy toxicity, not changes in the regimens themselves. 23 We propose that even though the chemotherapy regimens were varied within and between our study groups, it is possible that the chemotherapy regimens do not greatly affect the overall survival in OS patients.
Local recurrence rates in pathologic fracture patients range from 10% to 26% in different studies. [3] [4] [5] [6] 8, 19 We report a much lower rate of local recurrence that occurred in only one patient with pathologic fracture, yielding a rate of 2.9%. For the last three decades, two surgeons have performed most of the limb salvage or amputation procedures at our institution. The high volume of OS cases seen at our institution and the continuity of having the same surgical team caring for the majority of those cases, we believe contributed to the lower local recurrence rate among fracture patients.
Our results support those of other investigators when comparing functional outcomes between pathologic fracture patients and nonfracture patients. 5, 6 We found pathologic fracture patients had statistically significant worse functional outcomes compared to nonfrac- [2] [3] [4] [5] 20, 22 They attributed this to tumor dissemination. However, other investigators reported no decrease in overall survival in pathologic fracture patients. 7, 16, 21, 24, 25 Our results agree with the latter studies. There was no significant difference between the final outcomes in patients with a pathologic fracture and those without. A greater proportion of patients without pathologic fracture were alive at the last follow-up than those with fracture, but this was not statistically significant. In addition, there was no significant difference in the number of distant metastases between the two groups. Kim et al. reported that the presence of a pathologic fracture has no prognostic relevance in patients with localized OS. 25 Xie et al. concluded that limb salvage surgery could be used in patients with pathologic fracture without significantly increasing risk of distant metastasis. 7 Our results must be interpreted recognizing the limitations to this study. First, we had a small population size due to the rarity of pathologic fractures in OS patients. Second, selection bias could be invoked as it was conducted at a single institution with the same surgical team for 30 years. Third, we used a selected control group of 50 OS patients at St. Jude, but a different control group could yield different results.
Finally, we are also a large pediatric oncology center with many referral patients. This could yield some referral bias and possibly our patients represent a special group of more difficult OS patients.
On the basis of our results, we conclude that pathologic fractures in childhood and adolescent patients with OS are highly variable. Fracture management was highly variable and should be investigated further. The presence of a pathologic fracture did not increase the risk of local recurrence or distant metastases. Pathologic fracture, however, did result in lower functional outcomes when compared to nonfracture patients, but did not decrease overall survival.
